ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
ABBOTT LABORATORIES
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026
$104.06−0.83 (-0.79%)
Close on Oct 19, 2026
- Market cap
- $181.37B
- P/E (TTM)
- 33.5
- Dividend yield
- 2.31%
ABBOTT LABORATORIES revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medical Devices | $22.52B | $22.03B | $21.39B | $20.76B | $20.06B | $19.43B | $18.99B | $18.38B | $17.88B | $17.44B | $16.89B | $16.22B | 48.3% | +12.2% |
| Diagnostic Products | $9.98B | $9.06B | $8.94B | $9.00B | $9.16B | $9.18B | $9.34B | $9.36B | $9.39B | $9.51B | $9.99B | $10.73B | 21.4% | +9.0% |
| Nutritional Products | $8.25B | $8.32B | $8.45B | $8.64B | $8.55B | $8.49B | $8.41B | $8.32B | $8.33B | $8.26B | $8.15B | $7.93B | 17.7% | -3.5% |
| Established Pharmaceuticals | $5.82B | $5.70B | $5.54B | $5.42B | $5.32B | $5.23B | $5.19B | $5.15B | $5.11B | $5.10B | $5.07B | $5.06B | 12.5% | +9.4% |
| Operating income | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Medical Devices | $7.67B | $7.50B | $7.21B | $7.01B | $6.69B | $6.40B | $6.15B | $5.88B | $5.71B | $5.59B | $5.31B | $4.95B | +14.6% |
| Diagnostic Products | $1.84B | $1.72B | $1.74B | $1.74B | $1.90B | $1.96B | $2.07B | $2.18B | $2.25B | $2.26B | $2.43B | $2.75B | -3.0% |
| Nutritional Products | $1.43B | $1.48B | $1.56B | $1.62B | $1.57B | $1.52B | $1.51B | $1.42B | $1.40B | $1.33B | $1.33B | $1.13B | -9.1% |
| Established Pharmaceuticals | $1.39B | $1.36B | $1.29B | $1.31B | $1.30B | $1.26B | $1.23B | $1.22B | $1.18B | $1.17B | $1.21B | $1.17B | +7.6% |
By product or service
By region
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| International | $28.41B | $27.90B | $27.20B | $26.76B | $26.12B | $25.70B | $25.63B | $25.29B | $25.18B | $24.96B | $24.66B | $24.24B | 61.0% | +8.8% |
| United States | $18.17B | $17.23B | $17.13B | $17.08B | $16.99B | $16.65B | $16.32B | $15.93B | $15.55B | $15.37B | $15.45B | $15.72B | 39.0% | +7.0% |
From the segment and revenue-disaggregation notes of Abbott Laboratories's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.